An AA-tailored clinical prediction model will have improved discrimination relative to the PCPT RC for predicting Gleason >6 PCa in AAM undergoing prostate biopsy. Rationale: Many AAM undergo prostate biopsy unnecessarily and many others defer biopsies due to medical mistrust which could be ameliorated with a tailored RC for predicting high-risk PCa.[Halbert CH, Cancer, 2009] Thus, we will innovatively compare the effectiveness of the PCPT RC for high-risk PCa in AAM vs. EAM, tailor and internally validate a model from a retrospective AAM cohort and assess the performance of the AA-tailored prediction model relative to the PCPT RC in prospective recruited AAM eligible for prostate biopsy.
|Effective start/end date||9/15/17 → 9/14/20|
- U.S. Army Medical Research and Materiel Command (W81XWH-17-1-0608)